Roche Group said on Monday that it plans to invest more than $700 million in a new drug manufacturing facility in North ...

Pharma companies were mostly left out of the stock market’s broader rally Monday morning on the news that President Donald ...

Participants who took tirzepatide — which is sold as Zepbound by Eli Lilly — lost an average of 50 pounds over 72 weeks.

EXCLUSVE: LA-based production company Jingletown will be in Cannes to discuss a slate of projects including films produced ...

Eli Lilly’s weight loss drug Zepbound led to significantly greater weight loss than Novo Nordisk’s Wegovy in a 72-week, head-to-head clinical trial, according to findings published in The New England ...

A review of the film in Variety notes, “Patricia Clarkson can be larger-than-life… but the beauty of her performance in Lilly ...

Treatment with JAK inhibitors was associated with a greater risk of infections compared with biologic therapies in patients with atopic dermatitis.

In secondary endpoints, 64.6% of participants using Zepbound saw 15% weight loss compared with 40.1% on Wegovy. And Zepbound participants saw their waists reduced by an average 7.2 in (18.4 cm), ...

In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...

President Trump said he would sign an executive order to base U.S. drug prices on what other countries pay — usually far less ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.